Amodiaquine is a central drug in the new global strategy of combination therapies for the
control of malaria. Amodiaquine is mainly metabolized hepatically towards its major active …

Malaria is a major infectious disease. In the last 10 years it has killed more than 20 million
people, mainly small children in Africa. The highly efficacious artemisinine combination …

Metabolism of the antimalarial drug amodiaquine (AQ) into its primary metabolite, N‐
desethylamodiaquine, is mediated by CYP2C8. We studied the frequency of CYP2C8 …

Objective The determination of the prevalence of the CYP2C8 main alleles in a typical set of
malaria patients in Zanzibar, as these patients represent a typical population exposed to …

Some of the largest therapeutic drug exposures in the planet involve drugs employed
against malaria and TB, two main global infectious diseases. Amodiaquine for malaria and …

Abstract Background Cytochrome P450 (CYP) enzymes are essential in the metabolism of
most drugs used today. Single nucleotide polymorphism (s) occurring in CYP genes can …

Aims We assessed the disposition of oral amodiaquine (AQ) and CYP2C8 polymorphism in
20 children with falciparum malaria. Methods AQ and DEAQ concentrations were …

Abstract Amodiaquine (AQ) is a 4‐aminoquinoline widely used in the treatment of malaria as
part of the artemisinin combination therapy (ACT). AQ is metabolised towards its main …

Genetic variability in drug-metabolizing enzymes and drug transporters is known to
influence the pharmacokinetics of many drugs. Antimalarial drugs are a class of agents …

The prevention and management of malaria is primarily based on the use of drugs. Clinical
trials have however revealed that between individuals there is large variability in the …